Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Sang Myung Woo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3786-4403; OpenAlex author ID A5023470798. Sources: OpenAlex.

Their work

Papers
45 (first author 8, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 4 papers · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 4 papers · 2019: 4 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: 6 papers · 2025: 7 papers · 2026: 2 papers

Papers 45

  1. Impact of treatment sequence and dose response on outcomes in locally advanced pancreatic cancer treated with hypofractionated proton beam therapy using simult… Co-author DOI 10.1016/j.radonc.2025.111295↗
  2. Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-4517↗
  3. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  4. Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia. Co-author DOI 10.1016/j.esmogo.2025.100158↗
  5. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
  6. Effectiveness and cost analysis of liposomal irinotecan in patients with pancreatic adenocarcinoma: a multicenter real-world study. Last author DOI 10.1177/17588359251370492↗
  7. Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study. Last author DOI 10.3390/cancers17050896↗
  8. Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. First author DOI 10.3390/cancers17182988↗
  9. Loss of SLC25A20 in Pancreatic Adenocarcinoma Reversed the Tumor-Promoting Effects of a High-Fat Diet. Co-author DOI 10.7150/thno.114912↗
  10. PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. Co-author DOI 10.1016/j.xcrm.2024.101461↗
  11. New Function Annotation of PROSER2 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acs.jproteome.3c00632↗
  12. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. First author DOI 10.1111/cas.16104↗
  13. Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer. Last author DOI 10.3389/fonc.2024.1510016↗
  14. The Trends and Outcomes of Initial Palliative Chemotherapy in Patients with Pancreatic Cancer in Korea Based on National Health Insurance Service Data. Co-author DOI 10.3390/jcm13113229↗
  15. The Impact of the Dietary Inflammatory Index, Fasting Blood Glucose, and Smoking Status on the Incidence and Survival of Pancreatic Cancer: A Retrospective Cas… Co-author DOI 10.3390/nu16223941↗
  16. Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment. Co-author DOI 10.1016/j.jconrel.2023.03.048↗
  17. Exploring Connections between Oral Microbiota, Short-Chain Fatty Acids, and Specific Cancer Types: A Study of Oral Cancer, Head and Neck Cancer, Pancreatic Can… Co-author DOI 10.3390/cancers15112898↗
  18. Annotation-Efficient Deep Learning Model for Pancreatic Cancer Diagnosis and Classification Using CT Images: A Retrospective Diagnostic Study. Last author DOI 10.3390/cancers15133392↗
  19. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.291↗
  20. Endoscopic ultrasound-guided tissue acquisition for personalized treatment in pancreatic adenocarcinoma. Co-author DOI 10.5946/ce.2023.037↗
  21. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… First author DOI 10.1177/17588359221119539↗
  22. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Co-author DOI 10.3390/cancers13215466↗
  23. Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse. Co-author DOI 10.7150/thno.53935↗
  24. Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Co-author DOI 10.1038/s41598-020-78875-1↗
  25. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. First author DOI 10.1097/coc.0000000000000730↗
  26. ATP Production Relies on Fatty Acid Oxidation Rather than Glycolysis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12092477↗
  27. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2019.06.002↗
  28. Cytopathological results of initial endoscopic ultrasound-guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients. First author DOI 10.1111/cyt.12675↗
  29. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Sam… Co-author DOI 10.3389/fonc.2019.00875↗
  30. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuva… First author DOI 10.5009/gnl18355↗
  31. Favorable glycemic response after pancreatoduodenectomy in both patients with pancreatic cancer and patients with non-pancreatic cancer. Co-author DOI 10.1097/md.0000000000010590↗
  32. Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. Co-author DOI 10.1177/1533033818783879↗
  33. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1373/clinchem.2017.283721↗
  34. Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction c… Co-author DOI 10.3857/roj.2018.00073↗
  35. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine fo… Co-author DOI 10.4143/crt.2016.495↗
  36. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Co-author DOI 10.1016/j.pan.2016.09.001↗
  37. Development and Validation of a Prediction Model to Estimate Individual Risk of Pancreatic Cancer. First author DOI 10.1371/journal.pone.0146473↗
  38. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who hav… Last author DOI 10.1159/000356158↗
  39. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-8-160↗
  40. Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study. Co-author DOI 10.3346/jkms.2013.28.2.247↗
  41. Changes in dietary intake, body weight, nutritional status, and metabolic rate in a pancreatic cancer patient. Last author DOI 10.7762/cnr.2013.2.2.154↗
  42. Multiple primary malignant neoplasms in pancreatic cancer patients: a single-center experience in Korea. Co-author DOI 10.1097/mpa.0b013e3182374d65↗
  43. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.10.011↗
  44. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and u… Co-author DOI 10.1016/j.ijrobp.2011.02.063↗
  45. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182156d5a↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Woo Jin Lee · 31 shared papers, 2011–2026 · strength 3.76
  2. Jung Won Chun · 14 shared papers, 2022–2026 · strength 2.93
  3. Sang‐Jae Park · 25 shared papers, 2011–2025 · strength 2.40
  4. Sung‐Sik Han · 23 shared papers, 2011–2026 · strength 2.33
  5. Yun‐Hee Kim · 13 shared papers, 2016–2025 · strength 1.82
  6. Sun‐Young Kong · 12 shared papers, 2017–2025 · strength 1.79
  7. Jin‐Hyeok Hwang · 8 shared papers, 2013–2025 · strength 1.23
  8. Tae Hyun Kim · 13 shared papers, 2011–2025 · strength 0.93
  9. Soo‐Youl Kim · 5 shared papers, 2020–2026 · strength 0.90
  10. Min Kyeong Kim · 6 shared papers, 2017–2025 · strength 0.73
  11. Yoon Suk Lee · 4 shared papers, 2013–2025 · strength 0.72
  12. Dong Kee Jang · 3 shared papers, 2024–2025 · strength 0.68
  13. Young Ae Kim · 3 shared papers, 2024–2025 · strength 0.68
  14. Jong-Chan Lee · 4 shared papers, 2019–2025 · strength 0.65
  15. Yu‐Sun Lee · 4 shared papers, 2019–2025 · strength 0.63
  16. Sang Hyub Lee · 5 shared papers, 2011–2025 · strength 0.62
  17. Kyong‐Ah Yoon · 6 shared papers, 2017–2024 · strength 0.61
  18. Eun Kyung Hong · 10 shared papers, 2011–2021 · strength 0.60
  19. Mi Rim Lee · 3 shared papers, 2023–2025 · strength 0.56
  20. Hyonchol Jang · 3 shared papers, 2020–2026 · strength 0.46
  21. Hyeong Min Park · 2 shared papers, 2025 · strength 0.45
  22. Ji Kon Ryu · 4 shared papers, 2011–2025 · strength 0.41
  23. Min Kyu Jung · 2 shared papers, 2023–2025 · strength 0.40
  24. Mi Kyung Kim · 2 shared papers, 2023–2024 · strength 0.36
  25. Woo Hyun Paik · 2 shared papers, 2022–2025 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.